Cyclooxygenase-2 blockade can improve efficacy of VEGF-targeting drugs

Oncotarget

Volumn 6, Issue 8, 2015, Pages 6341-6358

  Ben Batalla, Isabel ^a   Cubas Cordova, Miguel ^a   Udonta, Florian ^a   Wroblewski, Mark ^a   Waizenegger, Jonas S ^a   Janning, Melanie ^a   Sawall, Stefanie ^a   Gensch, Victoria ^a   Zhao, Lin ^a   Martinez Zubiaurre, Iñigo ^b   Riecken, Kristoffer ^a   Fehse, Boris ^a   Pantel, Klaus ^a   Bokemeyer, Carsten ^a   Loges, Sonja ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Anti angiogenic therapies; Breast cancer; CAFs; Cox 2

Indexed keywords

4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2; FIBROBLAST GROWTH FACTOR 2; MONOCLONAL ANTIBODY DC101; PROSTAGLANDIN E2; PROTEIN KINASE B; SCATTER FACTOR; SUNITINIB; CYCLOOXYGENASE 2 INHIBITOR; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; CANCER ASSOCIATED FIBROBLAST; CANCER COMBINATION CHEMOTHERAPY; CANCER INFILTRATION; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; EMBRYO; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; IN VIVO STUDY; LOW DRUG DOSE; LUNG CANCER; MONOTHERAPY; MOUSE; NONHUMAN; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; MAMMARY NEOPLASMS, EXPERIMENTAL; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; RANDOMIZATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; VASCULARIZATION;

ANIMALS; CELL LINE, TUMOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MOLECULAR TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; RANDOM ALLOCATION; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84925685695     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3437     Document Type: Article

References (74)

1. Hanahan D and Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144:646-674.
2. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971; 285:1182-1186.
3. Carmeliet P. Angiogenesis in life, disease and medicine. Nature. 2005; 438:932-936.
4. Ferrara N and Kerbel RS. Angiogenesis as a therapeutic target. Nature. 2005; 438:967-974.
5. Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008; 358:2039-2049.
6. Welti J, Loges S, Dimmeler S and Carmeliet P. Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. The Journal of clinical investigation. 2013; 123:3190-3200.
7. Reinacher-Schick A, Pohl M and Schmiegel W. Drug insight: antiangiogenic therapies for gastrointestinal cancers-focus on monoclonal antibodies. Nat Clin Pract Gastroenterol Hepatol. 2008; 5:250-267.
8. Grothey A and Galanis E. Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nature reviews Clinical oncology. 2009; 6:507-518.
9. Meadows KL and Hurwitz HI. Anti-VEGF therapies in the clinic. Cold Spring Harbor perspectives in medicine. 2012; 2.
10. Kerbel RS. Reappraising antiangiogenic therapy for breast cancer. Breast. 2011; 20 Suppl 3:S56-60.
11. Wilke H. VCE, Oh S.C., Bodoky G., Shimada Y., Hironaka S., Sugimoto N., Lipatov O.N., Kim T.Y., Cunningham D., Ohtsu A., Rougier P., Emig M., Carlesi R., Chandrawansa K., Muro K. (2014). RAINBOW: A global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of metastatic gastroesophageal junction (GEJ) and gastric adenocarcinoma following disease progression on first-line platinum-and fluoropyrimidine-containing combination therapy rainbow IMCL CP12-0922 (I4T-IE-JVBE). 2014 Gastrointestinal Cancers Symposium.
12. Cortazar P, Justice R, Johnson J, Sridhara R, Keegan P and Pazdur R. US Food and Drug Administration approval overview in metastatic breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2012; 30:1705-1711.
13. Kollmannsberger C, Soulieres D, Wong R, Scalera A, Gaspo R and Bjarnason G. Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. Canadian Urological Association journal = Journal de l'Association des urologues du Canada. 2007; 1:S41-54.
14. Bergers G and Hanahan D. Modes of resistance to anti-angiogenic therapy. Nature reviews Cancer. 2008; 8:592-603.
15. Loges S, Schmidt T and Carmeliet P. Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates. Genes Cancer. 2010; 1:12-25.
16. Shojaei F, Wu X, Malik AK, Zhong C, Baldwin ME, Schanz S, Fuh G, Gerber HP and Ferrara N. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nature biotechnology. 2007; 25:911-920.
17. Murdoch C, Muthana M, Coffelt SB and Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nature reviews Cancer. 2008; 8:618-631.
18. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D and Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer cell. 2009; 15:220-231.
19. Maione F, Capano S, Regano D, Zentilin L, Giacca M, Casanovas O, Bussolino F, Serini G and Giraudo E. Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice. The Journal of clinical investigation. 2012; 122:1832-1848.
20. Gaustad JV, Simonsen TG, Leinaas MN and Rofstad EK. Sunitinib treatment does not improve blood supply but induces hypoxia in human melanoma xenografts. BMC cancer. 2012; 12:388.
21. Schmedtje JF, Jr., Ji YS, Liu WL, DuBois RN and Runge MS. Hypoxia induces cyclooxygenase-2 via the NF-kappaB p65 transcription factor in human vascular endothelial cells. The Journal of biological chemistry. 1997; 272:601-608.
22. Lee JJ, Natsuizaka M, Ohashi S, Wong GS, Takaoka M, Michaylira CZ, Budo D, Tobias JW, Kanai M, Shirakawa Y, Naomoto Y, Klein-Szanto AJ, Haase VH and Nakagawa H. Hypoxia activates the cyclooxygenase-2-prostaglandin E synthase axis. Carcinogenesis. 2010; 31:427-434.
23. Ruegg C, Dormond O and Mariotti A. Endothelial cell integrins and COX-2: mediators and therapeutic targets of tumor angiogenesis. Biochim Biophys Acta. 2004; 1654:51-67.
24. Howe LR, Subbaramaiah K, Patel J, Masferrer JL, Deora A, Hudis C, Thaler HT, Muller WJ, Du B, Brown AM and Dannenberg AJ. Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer research. 2002; 62:5405-5407.
25. Yoshinaka R, Shibata MA, Morimoto J, Tanigawa N and Otsuki Y. COX-2 inhibitor celecoxib suppresses tumor growth and lung metastasis of a murine mammary cancer. Anticancer research. 2006; 26:4245-4254.
26. Connolly EM, Harmey JH, O'Grady T, Foley D, Roche-Nagle G, Kay E and Bouchier-Hayes DJ. Cyclo-oxygenase inhibition reduces tumour growth and metastasis in an orthotopic model of breast cancer. British journal of cancer. 2002; 87:231-237.
27. Welti JC, Powles T, Foo S, Gourlaouen M, Preece N, Foster J, Frentzas S, Bird D, Sharpe K, van Weverwijk A, Robertson D, Soffe J, Erler JT, Pili R, Springer CJ, Mather SJ, et al. Contrasting effects of sunitinib within in vivo models of metastasis. Angiogenesis. 2012; 15:623-641.
28. Prewett M, Huber J, Li Y, Santiago A, O'Connor W, King K, Overholser J, Hooper A, Pytowski B, Witte L, Bohlen P and Hicklin DJ. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer research. 1999; 59:5209-5218.
29. Kaidi A, Qualtrough D, Williams AC and Paraskeva C. Direct transcriptional up-regulation of cyclooxygenase-2 by hypoxia-inducible factor (HIF)-1 promotes colorectal tumor cell survival and enhances HIF-1 transcriptional activity during hypoxia. Cancer research. 2006; 66:6683-6691.
30. Yao R, Rioux N, Castonguay A and You M. Inhibition of COX-2 and induction of apoptosis: two determinants of nonsteroidal anti-inflammatory drugs' chemopreventive efficacies in mouse lung tumorigenesis. Experimental lung research. 2000; 26:731-742.
31. Crawford Y, Kasman I, Yu L, Zhong C, Wu X, Modrusan Z, Kaminker J and Ferrara N. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer cell. 2009; 15:21-34.
32. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL and Weinberg RA. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 2005; 121:335-348.
33. Li F, Fan C, Zeng B, Zhang C, Chai Y, Liu S and Ouyang Y. Celecoxib suppresses fibroblast proliferation and collagen expression by inhibiting ERK1/2 and SMAD2/3 phosphorylation. Molecular medicine reports. 2012; 5:827-831.
34. Quante M, Tu SP, Tomita H, Gonda T, Wang SS, Takashi S, Baik GH, Shibata W, Diprete B, Betz KS, Friedman R, Varro A, Tycko B and Wang TC. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer cell. 2011; 19:257-272.
35. Polanska UM and Orimo A. Carcinoma-associated fibroblasts: non-neoplastic tumour-promoting mesenchymal cells. Journal of cellular physiology. 2013; 228:1651-1657.
36. Kalluri R and Zeisberg M. Fibroblasts in cancer. Nature reviews Cancer. 2006; 6:392-401.
37. Shimoda M, Mellody KT and Orimo A. Carcinoma-associated fibroblasts are a rate-limiting determinant for tumour progression. Seminars in cell & developmental biology. 2010; 21:19-25.
38. Kojima Y, Acar A, Eaton EN, Mellody KT, Scheel C, Ben-Porath I, Onder TT, Wang ZC, Richardson AL, Weinberg RA and Orimo A. Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proceedings of the National Academy of Sciences of the United States of America. 2010; 107:20009-20014.
39. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, Chan KW, Ciceri P, Davis MI, Edeen PT, Faraoni R, Floyd M, Hunt JP, Lockhart DJ, Milanov ZV, Morrison MJ, et al. A quantitative analysis of kinase inhibitor selectivity. Nature biotechnology. 2008; 26:127-132.
40. Welti JC, Gourlaouen M, Powles T, Kudahetti SC, Wilson P, Berney DM and Reynolds AR. Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib. Oncogene. 2011; 30:1183-1193.
41. Wei D, Wang L, He Y, Xiong HQ, Abbruzzese JL and Xie K. Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. Cancer research. 2004; 64:2030-2038.
42. Tortora G, Caputo R, Damiano V, Melisi D, Bianco R, Fontanini G, Veneziani BM, De Placido S, Bianco AR and Ciardiello F. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. Clinical cancer research: an official journal of the American Association for Cancer Research. 2003; 9:1566-1572.
43. Sobolewski C, Cerella C, Dicato M, Ghibelli L and Diederich M. The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies. International journal of cell biology. 2010; 2010:215158.
44. Vo BT, Morton D, Jr., Komaragiri S, Millena AC, Leath C and Khan SA. TGF-beta effects on prostate cancer cell migration and invasion are mediated by PGE2 through activation of PI3K/AKT/mTOR pathway. Endocrinology. 2013; 154:1768-1779.
45. Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K, Ueno Y, Hatch H, Majumder PK, Pan BS and Kotani H. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Molecular cancer therapeutics. 2010; 9:1956-1967.
46. De Wever O, Westbroek W, Verloes A, Bloemen N, Bracke M, Gespach C, Bruyneel E and Mareel M. Critical role of N-cadherin in myofibroblast invasion and migration in vitro stimulated by colon-cancer-cell-derived TGF-beta or wounding. Journal of cell science. 2004; 117:4691-4703.
47. Donovan J, Shiwen X, Norman J and Abraham D. Platelet-derived growth factor alpha and beta receptors have overlapping functional activities towards fibroblasts. Fibrogenesis & tissue repair. 2013; 6:10.
48. Al-Ansari MM, Hendrayani SF, Tulbah A, Al-Tweigeri T, Shehata AI and Aboussekhra A. p16INK4A represses breast stromal fibroblasts migration/invasion and their VEGF-A-dependent promotion of angiogenesis through Akt inhibition. Neoplasia. 2012; 14:1269-1277.
49. Dong L, Vecchio AJ, Sharma NP, Jurban BJ, Malkowski MG and Smith WL. Human cyclooxygenase-2 is a sequence homodimer that functions as a conformational heterodimer. The Journal of biological chemistry. 2011; 286:19035-19046.
50. Garavito RM, Malkowski MG and DeWitt DL. The structures of prostaglandin endoperoxide H synthases-1 and-2. Prostaglandins & other lipid mediators. 2002; 68-69:129-152.
51. Alexanian A, Miller B, Chesnik M, Mirza S and Sorokin A. Post-translational regulation of COX2 activity by FYN in prostate cancer cells. Oncotarget. 2014; 5:4232-4243.
52. Loges S, Mazzone M, Hohensinner P and Carmeliet P. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer cell. 2009; 15:167-170.
53. Garcia-Foncillas J, Martinez P, Lahuerta A, Llombart Cussac A, Garcia Gonzalez M, Sanchez Gomez RM, Alvarez I, Anton A, Illarramendi JJ, De Juan A, Galve Calvo E, Plazaola A, Morales S, Hernando B, Lao J, Boni V, et al. Dynamic contrast-enhanced MRI versus 18F-misonidazol-PET/CT to predict pathologic response in bevacizumab-based neoadjuvant therapy in breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2012; 30:(suppl; abstr 10512).
54. Conley SJ, Gheordunescu E, Kakarala P, Newman B, Korkaya H, Heath AN, Clouthier SG and Wicha MS. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109:2784-2789.
55. Fischer C, Jonckx B, Mazzone M, Zacchigna S, Loges S, Pattarini L, Chorianopoulos E, Liesenborghs L, Koch M, De Mol M, Autiero M, Wyns S, Plaisance S, Moons L, van Rooijen N, Giacca M, et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell. 2007; 131:463-475.
56. Casanovas O, Hicklin DJ, Bergers G and Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer cell. 2005; 8:299-309.
57. Wang X, Zhang L, O'Neill A, Bahamon B, Alsop DC, Mier JW, Goldberg SN, Signoretti S, Atkins MB, Wood CG and Bhatt RS. Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts. British journal of cancer. 2013; 108:319-326.
58. Blagosklonny MV. How Avastin potentiates chemotherapeutic drugs: action and reaction in antiangiogenic therapy. Cancer biology & therapy. 2005; 4:1307-1310.
59. Mueller L, Goumas FA, Himpel S, Brilloff S, Rogiers X and Broering DC. Imatinib mesylate inhibits proliferation and modulates cytokine expression of human cancer-associated stromal fibroblasts from colorectal metastases. Cancer letters. 2007; 250:329-338.
60. Chen HX and Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nature reviews Clinical oncology. 2009; 6:465-477.
61. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, Massimini G, Armand JP, Scigalla P and Raymond E. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2006; 24:25-35.
62. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clinical cancer research: an official journal of the American Association for Cancer Research. 2003; 9:327-337.
63. Kollmannsberger C, Bjarnason G, Burnett P, Creel P, Davis M, Dawson N, Feldman D, George S, Hershman J, Lechner T, Potter A, Raymond E, Treister N, Wood L, Wu S and Bukowski R. Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities. The oncologist. 2011; 16:543-553.
64. Jeong KH, Kim JY, Choi YS, Lee MY and Kim SY. Influence of aspirin on pilocarpine-induced epilepsy in mice. The Korean journal of physiology & pharmacology: official journal of the Korean Physiological Society and the Korean Society of Pharmacology. 2013; 17:15-21.
65. Shojaei F, Lee JH, Simmons BH, Wong A, Esparza CO, Plumlee PA, Feng J, Stewart AE, Hu-Lowe DD and Christensen JG. HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. Cancer research. 2010; 70:10090-10100.
66. Grosch S, Maier TJ, Schiffmann S and Geisslinger G. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. Journal of the National Cancer Institute. 2006; 98:736-747.
67. Kumar R, Crouthamel MC, Rominger DH, Gontarek RR, Tummino PJ, Levin RA and King AG. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. British journal of cancer. 2009; 101:1717-1723.
68. Kroll J and Waltenberger J. The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells. The Journal of biological chemistry. 1997; 272:32521-32527.
69. Huang S, Wettlaufer SH, Hogaboam C, Aronoff DM and Peters-Golden M. Prostaglandin E(2) inhibits collagen expression and proliferation in patient-derived normal lung fibroblasts via E prostanoid 2 receptor and cAMP signaling. American journal of physiology Lung cellular and molecular physiology. 2007; 292:L405-413.
70. Hellevik T, Pettersen I, Berg V, Winberg JO, Moe BT, Bartnes K, Paulssen RH, Busund LT, Bremnes R, Chalmers A and Martinez-Zubiaurre I. Cancer-associated fibroblasts from human NSCLC survive ablative doses of radiation but their invasive capacity is reduced. Radiation oncology. 2012; 7:59.
71. Ben-Batalla I, Schultze A, Wroblewski M, Erdmann R, Heuser M, Waizenegger JS, Riecken K, Binder M, Schewe D, Sawall S, Witzke V, Cubas-Cordova M, Janning M, Wellbrock J, Fehse B, Hagel C, et al. Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma. Blood. 2013; 122:2443-2452.
72. Kaur P, Nagaraja GM, Zheng H, Gizachew D, Galukande M, Krishnan S and Asea A. A mouse model for triple-negative breast cancer tumor-initiating cells (TNBC-TICs) exhibits similar aggressive phenotype to the human disease. BMC cancer. 2012; 12:120.
73. Phoenix KN, Vumbaca F, Fox MM, Evans R and Claffey KP. Dietary energy availability affects primary and metastatic breast cancer and metformin efficacy. Breast cancer research and treatment. 2010; 123:333-344.
74. Weber K, Mock U, Petrowitz B, Bartsch U and Fehse B. Lentiviral gene ontology (LeGO) vectors equipped with novel drug-selectable fluorescent proteins: new building blocks for cell marking and multi-gene analysis. Gene therapy. 2010; 17:511-520.